Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity
Objective: To compare ovulation inhibition and ovarian activity with 21-day and 24-day regimens of a low-dose combined oral contraceptive (COC) containing 60 μg of gestodene and 15 μg of ethinyl estradiol. Design: Interventional observational study. Setting: Reproductive medicine unit. Patient(s): F...
Gespeichert in:
| Veröffentlicht in: | Fertility and sterility 1999-07, Vol.72 (1), p.115-120 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 120 |
|---|---|
| container_issue | 1 |
| container_start_page | 115 |
| container_title | Fertility and sterility |
| container_volume | 72 |
| creator | Sullivan, Helen Furniss, Hilary Spona, Jurgen Elstein, Max |
| description | Objective: To compare ovulation inhibition and ovarian activity with 21-day and 24-day regimens of a low-dose combined oral contraceptive (COC) containing 60 μg of gestodene and 15 μg of ethinyl estradiol.
Design: Interventional observational study.
Setting: Reproductive medicine unit.
Patient(s): Fifty-eight healthy volunteers aged 18–35 years.
Intervention(s): Ovarian activity was monitored every other day with the use of ultrasound to measure the diameters of follicle-like structures and blood samples to measure serum concentrations of 17β-E
2 and progesterone. Subjects were observed for five cycles: pretreatment and posttreatment control cycles and three cycles in which the COC was administered for either 21 or 24 days of each cycle.
Main Outcome Measure(s): Occurrence of ovulation and evidence of ovarian activity.
Result(s): The study was completed by 27 (90%) of the 30 subjects who received the 24-day regimen and by 24 (79%) of the 28 subjects who received the 21-day regimen. Ovulation was inhibited in all cycles in the 24-day group and in 74 of 75 cycles in the 21-day group. Luteinized unruptured follicles were seen in no cycles with the 24-day regimen and in 6 (8%) of 75 cycles with the 21-day regimen. Mean ovarian follicular development and serum 17β-E
2 and progesterone levels were lower in the 24-day group.
Conclusion(s): The 24-day regimen is an innovative strategy for maintaining effective ovulation inhibition at ultra-low doses of contraceptive steroids. |
| doi_str_mv | 10.1016/S0015-0282(99)00205-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69928295</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0015028299002058</els_id><sourcerecordid>69928295</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-e87e67b8515578d990fbba9a3a27895e223410cb414935ebbaab76b670c52b113</originalsourceid><addsrcrecordid>eNqFkc2O0zAUhS0EYjoDjwDyAqHOImA7sWOvEBrNANJILIC1dePcFKPULnZaqW_AQ_EMPBNuUgE7VrZ8vvvjcwh5xtkrzrh6_YkxLismtFgbc82YYLLSD8iKS6kqqWT9kKz-IBfkMudvjDHFW_GYXHDWCM2lXpEft8OAbqJxoIJXPRwphJ6KZr7GBCN1MUwJHO4mf0CacOO3GPL8DD74sKEbzFPsMSBdK0Z__dxcz01w-urDcaRFTdD7ONI1l4scA40HSB4CBVf6-un4hDwaYMz49HxekS93t59v3lf3H999uHl7X7lGialC3aJqOy3LP1vdG8OGrgMDNYhWG4lC1A1nrmt4Y2qJRYOuVZ1qmZOi47y-Ii-XvrsUv-_Lbnbrs8NxhIBxn60yphhmZAHlAroUc0442F3yW0hHy5k9RWDnCOzJX2uMnSOwutQ9Pw_Yd1vs_6laPC_AizMA2cE4JAjO57-cES3nJ-zNgmFx4-Ax2ew8Boe9TyUx20f_n01-A1EAouA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69928295</pqid></control><display><type>article</type><title>Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><source>Alma/SFX Local Collection</source><creator>Sullivan, Helen ; Furniss, Hilary ; Spona, Jurgen ; Elstein, Max</creator><creatorcontrib>Sullivan, Helen ; Furniss, Hilary ; Spona, Jurgen ; Elstein, Max</creatorcontrib><description>Objective: To compare ovulation inhibition and ovarian activity with 21-day and 24-day regimens of a low-dose combined oral contraceptive (COC) containing 60 μg of gestodene and 15 μg of ethinyl estradiol.
Design: Interventional observational study.
Setting: Reproductive medicine unit.
Patient(s): Fifty-eight healthy volunteers aged 18–35 years.
Intervention(s): Ovarian activity was monitored every other day with the use of ultrasound to measure the diameters of follicle-like structures and blood samples to measure serum concentrations of 17β-E
2 and progesterone. Subjects were observed for five cycles: pretreatment and posttreatment control cycles and three cycles in which the COC was administered for either 21 or 24 days of each cycle.
Main Outcome Measure(s): Occurrence of ovulation and evidence of ovarian activity.
Result(s): The study was completed by 27 (90%) of the 30 subjects who received the 24-day regimen and by 24 (79%) of the 28 subjects who received the 21-day regimen. Ovulation was inhibited in all cycles in the 24-day group and in 74 of 75 cycles in the 21-day group. Luteinized unruptured follicles were seen in no cycles with the 24-day regimen and in 6 (8%) of 75 cycles with the 21-day regimen. Mean ovarian follicular development and serum 17β-E
2 and progesterone levels were lower in the 24-day group.
Conclusion(s): The 24-day regimen is an innovative strategy for maintaining effective ovulation inhibition at ultra-low doses of contraceptive steroids.</description><identifier>ISSN: 0015-0282</identifier><identifier>EISSN: 1556-5653</identifier><identifier>DOI: 10.1016/S0015-0282(99)00205-8</identifier><identifier>PMID: 10428158</identifier><identifier>CODEN: FESTAS</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Biological and medical sciences ; Cervix Mucus - drug effects ; Combined oral contraceptive ; Contraceptives, Oral, Synthetic - administration & dosage ; Drug Combinations ; Drug Evaluation ; Estradiol - blood ; Ethinyl Estradiol - administration & dosage ; Female ; Follicle Stimulating Hormone - blood ; Genital system. Reproduction ; gestodene ; Humans ; Luteinizing Hormone - blood ; Medical sciences ; Menstrual Cycle - drug effects ; Norpregnenes - administration & dosage ; Ovarian Follicle - diagnostic imaging ; Ovarian Follicle - drug effects ; Ovulation - drug effects ; ovulation inhibition ; Pharmacology. Drug treatments ; Progesterone Congeners - administration & dosage ; Ultrasonography ; ultrasound</subject><ispartof>Fertility and sterility, 1999-07, Vol.72 (1), p.115-120</ispartof><rights>1999 American Society for Reproductive Medicine</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-e87e67b8515578d990fbba9a3a27895e223410cb414935ebbaab76b670c52b113</citedby><cites>FETCH-LOGICAL-c462t-e87e67b8515578d990fbba9a3a27895e223410cb414935ebbaab76b670c52b113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0015-0282(99)00205-8$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1927118$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10428158$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sullivan, Helen</creatorcontrib><creatorcontrib>Furniss, Hilary</creatorcontrib><creatorcontrib>Spona, Jurgen</creatorcontrib><creatorcontrib>Elstein, Max</creatorcontrib><title>Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity</title><title>Fertility and sterility</title><addtitle>Fertil Steril</addtitle><description>Objective: To compare ovulation inhibition and ovarian activity with 21-day and 24-day regimens of a low-dose combined oral contraceptive (COC) containing 60 μg of gestodene and 15 μg of ethinyl estradiol.
Design: Interventional observational study.
Setting: Reproductive medicine unit.
Patient(s): Fifty-eight healthy volunteers aged 18–35 years.
Intervention(s): Ovarian activity was monitored every other day with the use of ultrasound to measure the diameters of follicle-like structures and blood samples to measure serum concentrations of 17β-E
2 and progesterone. Subjects were observed for five cycles: pretreatment and posttreatment control cycles and three cycles in which the COC was administered for either 21 or 24 days of each cycle.
Main Outcome Measure(s): Occurrence of ovulation and evidence of ovarian activity.
Result(s): The study was completed by 27 (90%) of the 30 subjects who received the 24-day regimen and by 24 (79%) of the 28 subjects who received the 21-day regimen. Ovulation was inhibited in all cycles in the 24-day group and in 74 of 75 cycles in the 21-day group. Luteinized unruptured follicles were seen in no cycles with the 24-day regimen and in 6 (8%) of 75 cycles with the 21-day regimen. Mean ovarian follicular development and serum 17β-E
2 and progesterone levels were lower in the 24-day group.
Conclusion(s): The 24-day regimen is an innovative strategy for maintaining effective ovulation inhibition at ultra-low doses of contraceptive steroids.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Cervix Mucus - drug effects</subject><subject>Combined oral contraceptive</subject><subject>Contraceptives, Oral, Synthetic - administration & dosage</subject><subject>Drug Combinations</subject><subject>Drug Evaluation</subject><subject>Estradiol - blood</subject><subject>Ethinyl Estradiol - administration & dosage</subject><subject>Female</subject><subject>Follicle Stimulating Hormone - blood</subject><subject>Genital system. Reproduction</subject><subject>gestodene</subject><subject>Humans</subject><subject>Luteinizing Hormone - blood</subject><subject>Medical sciences</subject><subject>Menstrual Cycle - drug effects</subject><subject>Norpregnenes - administration & dosage</subject><subject>Ovarian Follicle - diagnostic imaging</subject><subject>Ovarian Follicle - drug effects</subject><subject>Ovulation - drug effects</subject><subject>ovulation inhibition</subject><subject>Pharmacology. Drug treatments</subject><subject>Progesterone Congeners - administration & dosage</subject><subject>Ultrasonography</subject><subject>ultrasound</subject><issn>0015-0282</issn><issn>1556-5653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2O0zAUhS0EYjoDjwDyAqHOImA7sWOvEBrNANJILIC1dePcFKPULnZaqW_AQ_EMPBNuUgE7VrZ8vvvjcwh5xtkrzrh6_YkxLismtFgbc82YYLLSD8iKS6kqqWT9kKz-IBfkMudvjDHFW_GYXHDWCM2lXpEft8OAbqJxoIJXPRwphJ6KZr7GBCN1MUwJHO4mf0CacOO3GPL8DD74sKEbzFPsMSBdK0Z__dxcz01w-urDcaRFTdD7ONI1l4scA40HSB4CBVf6-un4hDwaYMz49HxekS93t59v3lf3H999uHl7X7lGialC3aJqOy3LP1vdG8OGrgMDNYhWG4lC1A1nrmt4Y2qJRYOuVZ1qmZOi47y-Ii-XvrsUv-_Lbnbrs8NxhIBxn60yphhmZAHlAroUc0442F3yW0hHy5k9RWDnCOzJX2uMnSOwutQ9Pw_Yd1vs_6laPC_AizMA2cE4JAjO57-cES3nJ-zNgmFx4-Ax2ew8Boe9TyUx20f_n01-A1EAouA</recordid><startdate>19990701</startdate><enddate>19990701</enddate><creator>Sullivan, Helen</creator><creator>Furniss, Hilary</creator><creator>Spona, Jurgen</creator><creator>Elstein, Max</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19990701</creationdate><title>Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity</title><author>Sullivan, Helen ; Furniss, Hilary ; Spona, Jurgen ; Elstein, Max</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-e87e67b8515578d990fbba9a3a27895e223410cb414935ebbaab76b670c52b113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Cervix Mucus - drug effects</topic><topic>Combined oral contraceptive</topic><topic>Contraceptives, Oral, Synthetic - administration & dosage</topic><topic>Drug Combinations</topic><topic>Drug Evaluation</topic><topic>Estradiol - blood</topic><topic>Ethinyl Estradiol - administration & dosage</topic><topic>Female</topic><topic>Follicle Stimulating Hormone - blood</topic><topic>Genital system. Reproduction</topic><topic>gestodene</topic><topic>Humans</topic><topic>Luteinizing Hormone - blood</topic><topic>Medical sciences</topic><topic>Menstrual Cycle - drug effects</topic><topic>Norpregnenes - administration & dosage</topic><topic>Ovarian Follicle - diagnostic imaging</topic><topic>Ovarian Follicle - drug effects</topic><topic>Ovulation - drug effects</topic><topic>ovulation inhibition</topic><topic>Pharmacology. Drug treatments</topic><topic>Progesterone Congeners - administration & dosage</topic><topic>Ultrasonography</topic><topic>ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sullivan, Helen</creatorcontrib><creatorcontrib>Furniss, Hilary</creatorcontrib><creatorcontrib>Spona, Jurgen</creatorcontrib><creatorcontrib>Elstein, Max</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fertility and sterility</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sullivan, Helen</au><au>Furniss, Hilary</au><au>Spona, Jurgen</au><au>Elstein, Max</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity</atitle><jtitle>Fertility and sterility</jtitle><addtitle>Fertil Steril</addtitle><date>1999-07-01</date><risdate>1999</risdate><volume>72</volume><issue>1</issue><spage>115</spage><epage>120</epage><pages>115-120</pages><issn>0015-0282</issn><eissn>1556-5653</eissn><coden>FESTAS</coden><abstract>Objective: To compare ovulation inhibition and ovarian activity with 21-day and 24-day regimens of a low-dose combined oral contraceptive (COC) containing 60 μg of gestodene and 15 μg of ethinyl estradiol.
Design: Interventional observational study.
Setting: Reproductive medicine unit.
Patient(s): Fifty-eight healthy volunteers aged 18–35 years.
Intervention(s): Ovarian activity was monitored every other day with the use of ultrasound to measure the diameters of follicle-like structures and blood samples to measure serum concentrations of 17β-E
2 and progesterone. Subjects were observed for five cycles: pretreatment and posttreatment control cycles and three cycles in which the COC was administered for either 21 or 24 days of each cycle.
Main Outcome Measure(s): Occurrence of ovulation and evidence of ovarian activity.
Result(s): The study was completed by 27 (90%) of the 30 subjects who received the 24-day regimen and by 24 (79%) of the 28 subjects who received the 21-day regimen. Ovulation was inhibited in all cycles in the 24-day group and in 74 of 75 cycles in the 21-day group. Luteinized unruptured follicles were seen in no cycles with the 24-day regimen and in 6 (8%) of 75 cycles with the 21-day regimen. Mean ovarian follicular development and serum 17β-E
2 and progesterone levels were lower in the 24-day group.
Conclusion(s): The 24-day regimen is an innovative strategy for maintaining effective ovulation inhibition at ultra-low doses of contraceptive steroids.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>10428158</pmid><doi>10.1016/S0015-0282(99)00205-8</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0015-0282 |
| ispartof | Fertility and sterility, 1999-07, Vol.72 (1), p.115-120 |
| issn | 0015-0282 1556-5653 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69928295 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier); Alma/SFX Local Collection |
| subjects | Adolescent Adult Biological and medical sciences Cervix Mucus - drug effects Combined oral contraceptive Contraceptives, Oral, Synthetic - administration & dosage Drug Combinations Drug Evaluation Estradiol - blood Ethinyl Estradiol - administration & dosage Female Follicle Stimulating Hormone - blood Genital system. Reproduction gestodene Humans Luteinizing Hormone - blood Medical sciences Menstrual Cycle - drug effects Norpregnenes - administration & dosage Ovarian Follicle - diagnostic imaging Ovarian Follicle - drug effects Ovulation - drug effects ovulation inhibition Pharmacology. Drug treatments Progesterone Congeners - administration & dosage Ultrasonography ultrasound |
| title | Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T21%3A47%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%2021-day%20and%2024-day%20oral%20contraceptive%20regimens%20containing%20gestodene%20(60%20%CE%BCg)%20and%20ethinyl%20estradiol%20(15%20%CE%BCg)%20on%20ovarian%20activity&rft.jtitle=Fertility%20and%20sterility&rft.au=Sullivan,%20Helen&rft.date=1999-07-01&rft.volume=72&rft.issue=1&rft.spage=115&rft.epage=120&rft.pages=115-120&rft.issn=0015-0282&rft.eissn=1556-5653&rft.coden=FESTAS&rft_id=info:doi/10.1016/S0015-0282(99)00205-8&rft_dat=%3Cproquest_cross%3E69928295%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69928295&rft_id=info:pmid/10428158&rft_els_id=S0015028299002058&rfr_iscdi=true |